Intellia Therapeutics
Intellia Therapeutics raises $350M Follow-on Offering at $4.5B valuation
Intellia Therapeutics: Follow-on Offering Funding Round
Intellia Therapeutics has successfully raised $350M in Follow-on Offering funding, reaching a valuation of $4.5B.
Company Overview
In vivo CRISPR gene editing
Funding Details
The Follow-on Offering round was led by Atlas Venture, with participation from Novartis Venture Fund, Venrock, Lilly Asia Ventures.
Company Information
- Headquarters: 40 Erie Street, Cambridge, MA 02139
- Founded: 2014
- Employees: 400+
- Category: Biotech
Investment
Intellia Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Atlas Venture: Verified investor in Follow-on Offering
- Novartis Venture Fund: Verified investor in Follow-on Offering
- Venrock: Verified investor in Follow-on Offering
- Lilly Asia Ventures: Verified investor in Follow-on Offering
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free